Mereo BioPharma Group plc
For the period ended Dec 31, 2025. Filed Mar 19, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 19, 2026
MREO$0.30+0.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated statements of operations and comprehensive loss
| Year Ended December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Revenue | $500 | $— |
| Operating expenses | ||
| Cost of revenue | (133) | — |
| Research and development | (17,766) | (20,930) |
| General and administrative | (23,008) | (26,434) |
| Other income | 300 | — |
| Loss from operations | (40,107) | (47,364) |
| Other income/(expenses) | ||
| Interest income | 2,173 | 3,041 |
| Interest expense | (255) | (1,370) |
| Changes in the fair value of warrants | 805 | (419) |
| Foreign currency transaction (loss)/gain, net | (6,344) | 1,210 |
| Benefit from research and development tax credit | 1,850 | 1,649 |
| Net loss before income tax | (41,878) | (43,253) |
| Income tax benefit | — | — |
| Net loss | $(41,878) | $(43,253) |
| Loss per share – basic and diluted | $(0.05) | $(0.06) |
| Weighted average shares outstanding – basic and diluted | 797,119,632 | 739,624,264 |
| Net loss | $(41,878) | $(43,253) |
| Other comprehensive income/(loss) – Foreign currency translation adjustments, net of tax | 8,026 | (1,364) |
| Total comprehensive loss | $(33,852) | $(44,617) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.